NCT03660969: H&M

Reliability of Cardiac Troponins for the Diagnosis of Myocardial Infarction in the Presence of Skeletal Muscle Disease

Active, enrolled Last updated 22 April 2025

What this trial tests

trial in Myopathy in 797 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 January 2018

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	797
Start date	1 January 2018
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	5 locations across Austria, Switzerland

Conditions studied

• Myopathy — all drugs for Myopathy →
• Muscle Weakness — all drugs for Muscle Weakness →
• Muscle Damage — all drugs for Muscle Damage →
• Muscle Spasticity — all drugs for Muscle Spasticity →

Sponsor

University Hospital, Basel, Switzerland

Who can join

18 and older, any sex, with Myopathy or Muscle Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Visits to the emergency department (ED) for chest pain are extremely common and require a safe, rapid and efficacious treatment algorithm to exclude a possible AMI. These diagnostic algorithms are partly based on an important laboratory value, which showed growing utility in the diagnostic and prognostic of many cardiovascular diseases in the last years : cardiac troponin.

However, some patients with muscle disease often present with unexplained elevated high-sensitive cardiac Troponin T (hs-cTnT) levels in the absence of cardiac disease. The investigators aim at the characterization of the behaviour of this biomarker and its alternative (high-sensitive cardiac Troponin I), which will have important clinical implications on patients management.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Skeletal Muscle Disorders: A Noncardiac Source of Cardiac Troponin T.
   du Fay de Lavallaz J, Prepoudis A, Wendebourg MJ, Kesenheimer E, et al · · 2022 · cited 87× · PMID 35389756 · DOI 10.1161/circulationaha.121.058489